Clinical Trials

Accrual Status
Limit to SWOG Trials

1045 Results

View
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0777

A Randomized Phase III Trial of CC-5013 (lenalidomide, NSD-703813) and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant
Status Notes
Revision #24 requires sites to contact all patients that have been enrolled, including those that have completed treatment and follow-up, to offer them participation in extended follow-up.
Research Committee(s)
Myeloma
Activated
04-01-2008
Closed
02-01-2012
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0727

A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First Line Treatment in Patients with Metastatic Pancreatic Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
03-01-2008
Closed
09-01-2010
ClinicalTrials.gov Registry Number
NCT00617708
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0518

Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Research Committee(s)
Gastrointestinal Cancer
Activated
12-01-2007
Closed
09-01-2012
ClinicalTrials.gov Registry Number
NCT00569127
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S0535

A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Research Committee(s)
Leukemia
Activated
11-15-2007
ClinicalTrials.gov Registry Number
NCT00551460
Closed
Phase
Accrual
91%
Published
SWOG Clinical Trial Number
S0438

A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma
Research Committee(s)
Melanoma
Activated
08-01-2007
Closed
11-15-2009
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S0337

A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer
Research Committee(s)
Genitourinary Cancer
Activated
07-15-2007
Closed
08-15-2012
ClinicalTrials.gov Registry Number
NCT00445601
Closed
Phase
Accrual
95%
SWOG Clinical Trial Number
S0635

A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features
Research Committee(s)
Lung Cancer
Activated
07-15-2007
Closed
08-15-2011
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S0636

A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas
Research Committee(s)
Lung Cancer
Activated
07-15-2007
Closed
09-01-2010
Closed
Phase
Accrual
11%
Published
SWOG Clinical Trial Number
S0600

Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX
Research Committee(s)
Gastrointestinal Cancer
Activated
06-15-2007
Closed
11-10-2010
ClinicalTrials.gov Registry Number
NCT00499369
Closed
Phase
Accrual
19%
Published
SWOG Clinical Trial Number
S0521

A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III
Research Committee(s)
Leukemia
Activated
06-01-2007
ClinicalTrials.gov Registry Number
NCT00492856
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0354

A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6) in Patients with Hormone Refractory Prostate Cancer
Research Committee(s)
Genitourinary Cancer
Activated
04-01-2007
Closed
05-15-2008
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0622

Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer
Research Committee(s)
Breast Cancer
Activated
03-15-2007
Closed
12-15-2010
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0353

Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Research Committee(s)
Genitourinary Cancer
Activated
11-15-2006
Closed
10-15-2009
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0408

A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin and Bevacizumab for Resectable Colorectal Metastases in the Liver
Research Committee(s)
Gastrointestinal Cancer
Activated
11-15-2006
Closed
04-01-2007
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0530

A Phase II Trial of Cytarabine and Clofarabine in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Research Committee(s)
Leukemia
Activated
10-01-2006
Closed
08-01-2008
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0500

A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
Research Committee(s)
Breast Cancer
Activated
10-01-2006
Closed
03-15-2012
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0528

Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989; IND-75,093) and Everolimus (RAD001; NSC-733504; IND-75,093) in Patients with Advanced Solid Tumors
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
09-01-2006
Closed
08-25-2009
ClinicalTrials.gov Registry Number
NCT00352443
Closed
Phase
Accrual
99%
Published
SWOG Clinical Trial Number
S0421

Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
Research Committee(s)
Genitourinary Cancer
Activated
08-21-2006
Closed
05-01-2010
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0601

A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
08-15-2006
Closed
06-01-2008
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0506

Phase II Trial of PS-341 (Bortezomib, NSC-681239) Followed by the Addition of Gemcitabine at Progression in Recurrent or Metastatic Nasopharyngeal Carcinoma
Research Committee(s)
Head and Neck Cancer
Activated
08-15-2006
Closed
01-10-2007